

**Systemic Administration of a
Connexin43 Mimetic Peptide:
A Treatment Option for
Spinal Cord Injury**

*A thesis submitted in fulfilment of the requirements for the
degree of Doctor of Philosophy*

Yilin Mao

2017

**School of Life Sciences
Faculty of Science
University of Technology Sydney**

Certificate of Original Authorship

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as part of the collaborative doctoral degree and/or fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This research is supported by an Australian Government Research Training Program Scholarship.

Signature of Student:

Date: 20/05/2017

Acknowledgements

First of all, I would like to express my appreciation to my principle supervisor, Dr. Catherine Gorrie, for your guidance, patience, expertise, intelligence, encouragement and dedication inspiring me. I cherish the liveliest feeling of sincere gratitude for you, not only in academics but also personality. Without your endless direction and instruction in the past four years, I would not have made so much achievement today.

I also wish to thank my co-supervisors, Dr. Hui Chen and Dr. Gila Moalem-Taylor, for your continuous advice and support during my PhD training. Your invaluable mentoring has made my research life so much easier.

To my wise and patient collaborators from the University of Auckland, Dr. Simon O'Carroll, Prof. Louise Nicholson and Prof. Colin Green, thank you for providing professional comments on my research project and manuscripts.

Thank you to all other smart people working for this project: Tara Nguyen, being the research assistant, for your indispensable help in the animal surgeries, post-operative care, euthanasia, locomotion assessments, histology staining and immunohistochemistry; Ryan Tonkin, for providing assistance in the animal surgeries, post-operative care, pain hypersensitivity assessments, western blot and multiplex ELISA; and Justin Lees, for your generous aid in multiplex ELISA.

I want to express my sincere appreciation to the staff in University of Technology Sydney Ernst Facility for taking care of experimental animals, Microbial Imaging Facility for providing the fluorescent microscopies and associated softwares, and Proteomics Core Facility for assistance mass spectrometry and electrophoresis imaging.

I would like to acknowledge all funding organisations, Australian Government, Australasian Spinal Cord Injury Network, CatWalk Spinal Cord Injury Research Trust New Zealand and University of Technology Sydney, for providing me the financial support in the form of research grants, scholarships, travel funds for conferences and in-kind support.

I also want to acknowledge Elite Editing for editing my PhD thesis, in accordance with Standards D and E of the Australian Standards for Editing Practice, and Perry Kwong for proofreading my PhD thesis.

Special thanks to Jeremy Chan, for giving me suggestions in not only laboratory works but, more importantly, personal life.

To all other members at Neural Injury Research Unit - Thomas C, Katheryn, Theresa, Alison, Arjun, Razia, Thomas H and Claire – thank you for your help and kindness during the experimental works in our compact laboratory.

To Coco Kuang, my soul mate, thank you for your accompany during my darkest age of PhD candidature, enduring my frustration and disappointment from the experiments, as well as bringing me to greet the promising dawn.

To Wilson, Jin, Jiaxin, Fiona, Kimmy, Kim, Mashiry and all my great friends around the world, thank you for giving me so many good memories and always helping me escape from the blue periods.

To my lovely family, dad and mum, I want to thank you for your unconditional love and support all the time.

Table of Contents

Certificate of Original Authorship	i
Acknowledgements	ii
Table of Contents	iv
List of Figures	viii
List of Tables	x
Abbreviation	xi
Publications Arising from PhD Research	xiii
Other Publications during PhD Candidature	xiv
Conference Proceedings Arising from PhD Research	xv
Awards and Scholarships	xvi
Abstract	xvii
1. Chapter 1 General Introduction	1
1.1 Epidemiology of spinal cord injury	2
1.2 Pathophysiology of spinal cord injury	6
1.2.1 Primary injury	6
1.2.2 Secondary injury	8
1.2.3 Astroglial scar formation	9
1.2.4 Inflammatory cells	12
1.2.4.1 Activation of resident microglia	13
1.2.4.2 Penetration of circulating neutrophils	14
1.2.4.3 Recruitment of blood-borne monocytes	15
1.2.4.4 Infiltration of lymphocytes	16
1.2.5 Neurotoxic molecules	18
1.2.6 Gap junctional communication	19
1.3 Present clinical approaches for spinal cord injury	23
1.3.1 Methylprednisolone to limit secondary injury	23
1.3.2 Surgical stabilisation and decompression	25
1.3.3 Multisystem medical management	25

1.3.4 Functional rehabilitation	27
1.4 Current research on Connexin43 for spinal cord injury repair	28
1.4.1 Genetic deletion of Connexin43	29
1.4.2 Gap junction inhibitors	30
1.4.3 Connexin43 antisense oligodeoxynucleotides.....	31
1.4.4 Connexin43 mimetic peptides	34
1.5 Project overview.....	37
1.5.1 Hypotheses and aims.....	38
2. Chapter 2 Optimisation of the peptide5 Systemic Administration Protocol for Traumatic Spinal Cord Injury	40
2.1 Introduction	41
2.2 Materials and methods.....	43
2.2.1 Preparation of peptides.....	43
2.2.2 Mass spectrometry	44
2.2.3 Electrophoresis	45
2.2.4 Animals and general care	46
2.2.5 Surgical procedures	47
2.2.6 Peptide treatment	48
2.2.7 Post-operative care	49
2.2.8 Behavioural assessments.....	49
2.2.9 Euthanasia	51
2.2.10 Western blot.....	51
2.2.11 Histology	52
2.2.12 Fluorescent immunohistochemistry.....	53
2.2.13 Imaging and quantification.....	54
2.2.14 Statistical analysis.....	55
2.3 Results.....	56
2.3.1 Degradation curves of Peptide5 <i>in vitro</i>	56
2.3.1.1 Mass spectrometry	56
2.3.1.2 Electrophoresis	57
2.3.2 Consistent spinal cord injury in rats	59
2.3.3 Dosing responses of Peptide5	61
2.3.4 Systemic delivery of Peptide5 to the lesion.....	63
2.4 Discussion	67

3. Chapter 3 Investigation of Cellular and Functional Improvement in Spinal Cord Injury Rats from the Peptide5 Systemic Administration	72
3.1 Introduction	73
3.2 Materials and methods	75
3.2.1 Animals and general care	75
3.2.2 Surgical procedures	75
3.2.3 Peptide treatment	76
3.2.4 Post-operative care	76
3.2.5 Behavioural assessments.....	76
3.2.5.1 Locomotor function	76
3.2.5.2 Pain hypersensitivity	77
3.2.6 Euthanasia and histology.....	78
3.2.7 Fluorescent immunohistochemistry	79
3.2.8 Imaging and quantification.....	81
3.2.9 Statistical analysis.....	82
3.3 Results	83
3.3.1 Consistent spinal cord injury in rats	83
3.3.2 Connexin43 and phosphorylated Connexin43.....	84
3.3.3 Lesion size.....	87
3.3.4 Astrogliosis (GFAP immunohistochemistry)	89
3.3.5 Microglial/macrophage activation (Iba1&ED1 immunohistochemistry)	91
3.3.6 Neuronal survival (NeuN immunohistochemistry)	93
3.3.7 Motor function (Open field and horizontal ladder tests)	96
3.3.8 Sensory function (Mechanical allodynia).....	97
3.4 Discussion	99
4. Chapter 4 Safety Profile of the Peptide5 Systemic Administration for Traumatic Spinal Cord Injury	106
4.1 Introduction	107
4.2 Materials and methods	109
4.2.1 Distribution of Peptide5 <i>in vivo</i>	109
4.2.1.1 Animals and general care.....	109
4.2.1.2 Surgical procedures.....	109
4.2.1.3 Euthanasia and tissue preparation	110
4.2.2 Connexin43 protein in the heart and lung tissue	110

4.2.2.1 Histology on the heart and lung tissue	111
4.2.1.2 Immunohistochemistry on the heart and lung tissue	112
4.2.3 Major connexin proteins in the spinal cord tissue.....	113
4.2.3.1 Cellular distribution of major connexins in the spinal cord tissue	113
4.2.3.1 Quantification of major connexins in the spinal cord tissue.....	115
4.2.4 Imaging and quantification	116
4.2.5 Inflammatory effects in plasma	116
4.2.6 Statistical analysis	117
4.3 Results.....	118
4.3.1 Distribution of Peptide5 <i>in vivo</i>	118
4.3.2 Connexin43 protein in the heart tissue	120
4.3.3 Connexin43 protein in the lung tissue	122
4.3.4 Major connexin proteins in the spinal cord tissue.....	123
4.3.5 Inflammatory effects in plasma	128
4.4 Discussion	129
5. Chapter 5 General Discussion.....	137
5.1 Project summary	138
5.2 Future directions	141
5.3 Conclusion	144
Bibliography	145
Appendix – Reagent Specifications	181

List of Figures

Figure 1.1 The severity of SCI measured by neurological level of injury and extent of injury.....	4
Figure 1.2 The formation of astroglial scar following spinal cord injury in humans.	11
Figure 1.3 Temporal response of inflammatory cells in spinal cord injury rats.....	12
Figure 1.4 Illustration of gap junction (A) and connexin (B) structures in vertebrates..	20
Figure 2.1 Schematic diagram of the Multicentre Animal Spinal Cord Injury Study impactor.....	48
Figure 2.2 Mass spectrometry analysis of Peptide5 degradation in normal rat serum <i>in vitro</i>	56
Figure 2.3 Electrophoresis analysis of Peptide5 degradation in normal rat and human sera <i>in vitro</i>	58
Figure 2.4 Surgical parameters for Cohort I showing the means of (A) weight-drop velocity in m/s, (B) compression in mm and (C) compression rate in m/s with standard error of the mean.....	60
Figure 2.5 Behavioural assessment of hind limb locomotor function for Cohort I.....	60
Figure 2.6 Surgical parameters for Cohort II showing the means of (A) weight-drop velocity in m/s, (B) compression in mm and (C) compression rate in m/s with standard error of the mean.....	61
Figure 2.7 Western blot analysis of Connexin43 and phosphorylated Connexin43 protein levels at the injury site 24 hours following surgery.....	62
Figure 2.8 Changes in lesion size at 8 hours following spinal cord contusion injury. ...	63
Figure 2.9 Immunohistochemistry staining of Connexin43 at 8 hours following spinal cord injury.....	65
Figure 2.10 Immunohistochemistry staining of phosphorylated Connexin43 at 8 hours following spinal cord injury.....	66
Figure 3.1 Immunohistochemistry staining of Connexin43 at 24 hours following spinal cord injury.....	85
Figure 3.2 Immunohistochemistry staining of phosphorylated Connexin43 at 24 hours following spinal cord injury.....	86
Figure 3.3 Changes in lesion size following spinal cord contusion injury.....	88

Figure 3.4 Glial fibrillary acidic protein (GFAP) expression following spinal cord contusion injury.	90
Figure 3.5 Activation of microglia and/or macrophages at the lesion edge following spinal cord contusion injury.....	92
Figure 3.6 Surviving neuronal cells following spinal cord contusion injury.....	95
Figure 3.7 Locomotor function assessments following spinal cord injury.....	97
Figure 3.8 Sensory function assessments following spinal cord injury.....	98
Figure 4.1 Distribution of fluorescein isothiocyanate labelled Peptide5 in normal and spinal cord injury rats.....	119
Figure 4.2 Histological morphology and the immunohistochemistry staining of Connexin43 and phosphorylated Connexin43 in the heart tissue.....	121
Figure 4.3 Histological morphology and the immunohistochemistry staining of Connexin43 in the lung tissue.....	122
Figure 4.4 Immunohistochemistry co-labelling of major connexin proteins and neural markers at 8 hours following spinal cord injury.	124
Figure 4.5 Immunohistochemistry staining of Connexin30 in rat spinal cord at 8 and 24 hours following injury.....	125
Figure 4.6 Immunohistochemistry staining of Connexin36 in rat spinal cord at 8 and 24 hours following injury.....	126
Figure 4.7 Immunohistochemistry staining of Connexin47 in rat spinal cord at 8 and 24 hours following injury.....	127

List of Tables

Table 1.1 Medical management for people with spinal cord injury (Becker et al., 2003).	26
Table 1.2 Summary of clinical trials for Nexagon®.....	33
Table 1.3 Summary of animal cohorts and tissue samples obtained in the current study	39
Table 2.1 Basso, Beattie, and Bresnahan locomotor rating scale (Basso et al., 1996)...	50
Table 2.2 Summary of filter characteristics for fluorescent imaging.	54
Table 3.1 Summary of antibody characteristics for immunohistochemistry.	80
Table 3.2 Consistent contusion spinal cord injury produced in rats.	83
Table 4.1 Summary of the heart and lung samples used for the Connexin43 study.....	111
Table 4.2 The routine overnight processing programme for histology.	112
Table 4.3 Summary of antibody characteristics for immunohistochemistry co-labelling of connexins and neural markers.	114
Table 4.4 Summary of the spinal cord samples used for quantification of major connexins.	115
Table 4.5 Summary of antibody characteristics for immunohistochemistry of major connexins.	115
Table 4.6 Comparison of cytokines, chemokines and growth factors in rat plasma. ...	128

Abbreviation

3Rs:	Replacement, Reduction and Refinement
ACEC:	Animal Care and Ethics Committee
AMPA:	a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
ANOVA:	Analysis of Variance
AS-ODN:	Antisense oligodeoxynucleotide
ATP:	Adenosine triphosphate
BBB:	Basso, Beattie and Bresnahan
BSB:	Blood spinal cord barrier
CNS:	Central nervous system
FITC:	Fluorescein isothiocyanate
FL:	Front limb
GABA:	γ -aminobutyric acid
GFAP:	Glial fibrillary acidic protein
H&E:	Haematoxylin and Eosin
HL:	Hind limb
HREC:	Human Research Ethics Committee
IHC:	Immunohistochemistry
MASCIS:	Multicentre Animal Spinal Cord Injury Study
MP:	Methylprednisolone
mRNA:	Messenger ribonucleic acid
MS:	Mass spectrometry
NASCIS:	National Acute Spinal Cord Injury Studies
NeuN:	Neuronal nuclei
NGS:	Normal goat serum
NMDA:	N-methyl-D-aspartate
OSP:	Oligodendrocyte Specific Protein
P5:	Peptide5
PBG:	Phosphate buffer with 5% normal goat serum
PFA:	Paraformaldehyde
ROS:	Reactive oxygen species
SCI:	Spinal cord injury

SDS:	Sodium dodecyl sulphate
SEM:	Standard error of the mean
SP:	Scrambled peptide
TBS:	Tris-buffered saline
UNSW:	University of New South Wales
UTS:	University of Technology Sydney

Publications Arising from PhD Research

MAO, Y., TONKIN, R.S., NGUYEN, T., O'CARROLL, S.J., NICHOLSON, L.F., GREEN, C.R., MOALEM-TAYLOR, G. and GORRIE, C.A., 2017. Systemic Administration of Connexin43 Mimetic Peptide Improves Functional Recovery after Traumatic Spinal Cord Injury in Adult Rats. *Journal of Neurotrauma* 33, 707-719.

TONKIN, R. S., **MAO, Y.**, O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., GORRIE, C. A. & MOALEM-TAYLOR, G. 2014. Gap junction proteins and their role in spinal cord injury. *Frontiers in Molecular Neuroscience* 7.

Other Publications during PhD Candidature

SUTHERLAND, T.C., MATHEWS, K.J., **MAO, Y.**, NGUYEN, T. & GORRIE, C.A. 2017. Differences in the cellular response to acute spinal cord injury between developing and mature rats highlights the potential significance of the inflammatory response. *Frontiers in Cellular Neuroscience* 10, 310.

CHEN, H., Chan, Y.L., NGUYEN, L.T., **MAO, Y.**, de ROSA, A., Beh, I.T., CHEE, C., OLIVER, B., HEROK, G., SAAD, S. & GORRIE, C., 2016. Moderate traumatic brain injury is linked to acute behaviour deficits and long term mitochondrial alterations. *Clinical and Experimental Pharmacology and Physiology* 43, 1107-1114.

MAO, Y., NGUYEN, T., SUTHERLAND, T. & GORRIE, C. A. 2016. Endogenous neural progenitor cells in the repair of the injured spinal cord. *Neural Regeneration Research*, 11, 1075-1076.

MAO, Y., MATHEWS, K. & GORRIE, C. A. 2016. Temporal response of endogenous neural progenitor cells following injury to the adult rat spinal cord. *Frontiers in Cellular Neuroscience* 10.

Conference Proceedings Arising from PhD

Research

MAO, Y., TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., MOALEM-TAYLOR, G. & GORRIE, C. A., 2017. Systemic administration of a Connexin43 mimetic peptide is neuroprotective and improves functional recovery after spinal cord injury in rats. *BNA 2017 Festival of Neuroscience*, Birmingham, UK: British Neuroscience Association.

MAO, Y., TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., MOALEM-TAYLOR, G. & GORRIE, C. A., 2016. Systemic administration of a Connexin43 mimetic peptide in rats improves functional recovery after spinal cord injury. *Australasian Neuroscience Society Annual Conference*, Hobart, TAS: Australasian Neuroscience Society.

GORRIE, C. A., **MAO, Y.,** TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R. & MOALEM-TAYLOR, G. 2016. Modulation of Connexin43 hemichannels following mild spinal cord injury. *Australasian Neuroscience Society Annual Conference*, Hobart, TAS: Australasian Neuroscience Society.

MAO, Y., TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., MOALEM-TAYLOR, G. & GORRIE, C. A., 2016. Systemic delivery of a Connexin43 hemichannel blocking mimetic peptide improves functional recovery following spinal cord injury in rats. *Neuroscience 2016*, San Diego, California: Society for Neuroscience.

MAO, Y., TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., MOALEM-TAYLOR, G. & GORRIE, C. A., 2015. Systemic delivery of a Connexin43 mimetic peptide in rats improves hindlimb locomotor function following spinal cord injury. *New Horizons Combined Health Science Conference*, Sydney, NSW: NSW Health Government.

MAO, Y., TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., MOALEM-TAYLOR, G. & GORRIE, C. A., 2015. Systemic delivery of a connexin43 hemichannel blocking mimetic peptide in rats improves hindlimb locomotor function following spinal cord injury. *Inter-university Neuroscience and Mental Health Conference*. Sydney, NSW: Brain Sciences UNSW.

MAO, Y., TONKIN, R. S., NGUYEN, T., O'CARROLL, S. J., NICHOLSON, L. F., GREEN, C. R., MOALEM-TAYLOR, G. & GORRIE, C. A., 2015. Systemic delivery of a mimetic peptide against connexin43 gap junction protein in rats following spinal cord injury. *Australasian Neuroscience Society Annual Conference*. Cairns, QLD: Australasian Neuroscience Society.

Awards and Scholarships

UTS Faculty of Science HDR Student Conference Fund	2017
Australasian Spinal Cord Injury Network Travel Grants	2016/2017
UTS Vice-Chancellor's Postgraduate Research Student Conference Fund	2016 & 2017
Australian Government Research Training Program Scholarship	2015-2017
UTS Doctoral Scholarship	2015-2017
UTS President Scholarship	2014-2015
UTS International Research Scholarship	2014-2015
UTS Science Dean's Merit List Award	2014

Abstract

Spinal cord injury (SCI) is a major cause of morbidity, and leads to significant physical, emotional and financial burdens for individuals and their families. There is no known cure to date and current treatment options are limited. A cascade of secondary tissue damage starts within minutes to hours of an initial traumatic SCI, worsening the cellular and functional recovery. The time course of secondary damage does, however, offer a potential window of opportunity for intervention. It may be possible to administer new therapeutics during this early period, to prevent the extensive spread of damage to adjacent healthy tissue.

Over the past two decades, regulation of Connexin43 hemichannels has provided a novel avenue of research into limiting the secondary damage of SCI. Peptide5, a Connexin43 mimetic peptide, is a promising candidate that shows efficacy in blocking Connexin43 hemichannels, thus preventing the propagation of neurotoxic molecules from the injured cells to the nearby intact tissue in a number of neural injury models. Peptide5, in particular, has been shown to reduce secondary tissue damage and to improve functional recovery when delivered directly to the site of SCI. However, direct application of peptides to a spinal cord lesion is likely to be impractical in a clinical setting, and might result in delays to the initiation of treatment. Therefore, the current research project aims to demonstrate that the systemic administration of Peptide5 is a clinically relevant treatment option for traumatic SCI by (1) optimising the systemic administration protocol of Peptide5; (2) investigating the cellular and function improvements in SCI rats from the Peptide5 systemic administration; and (3) examining the safety profile of Peptide5 systemic administration protocol.

Mass spectrometry and electrophoresis were used to determine the *in vitro* degradation curves in normal rat and human sera. A rat model of contusive SCI was then employed to optimise the dosing regimen and investigate the efficacy of Peptide5 in limiting secondary tissue damage and improving functional recovery. The lesion size was assessed on Haematoxylin and Eosin stained histological sections, and fluorescent immunohistochemistry was utilised to examine the Connexin43 protein and hemichannels, as well as cellular responses. The behavioural improvements were evaluated from motor (open field and error ladder tests) and sensory (mechanical pain hypersensitivity) functions. Fluorescent-labelled Peptide5 was delivered to the SCI and normal rats systemically in order to determine the *in vivo* distribution.

It was found that the *in vitro* half-life of Peptide5 was 2 hours in normal rat serum and that the most effective dosing regimen was three injections of Peptide5 at 0 (10 mg/kg), 2 (5 mg/kg) and 4 (2.5 mg/kg) hours post-injury. Compared with controls, Peptide5 treated rats showed significant improvements in hind limb locomotor function and mechanical pain hypersensitivity. Peptide5 treatment led to a reduction in Connexin43 protein level, hemichannel opening, lesion size, astrogliosis, macrophage and/or microglial activation, and neuronal cell death. There was no evidence to suggest that Peptide5 had any adverse systemic effects in normal and SCI animals, or influenced other connexins in the spinal tissue.

The current research project demonstrated that systemic administration of Peptide5 is a feasible, neuroprotective and safe treatment option for ameliorating secondary damage and improving functional recovery in a contusive SCI model of rats. These findings provide strong support for the clinical use of Peptide5 in the near future.